Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Lubiprostone: a novel treatment for chronic constipation

Authors Brian E Lacy, L Campbell Levy

Published Date June 2008 Volume 2008:3(2) Pages 357—364

DOI http://dx.doi.org/10.2147/CIA.S2938

Published 30 June 2008

Brian E Lacy, L Campbell Levy

Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USA

Abstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.

Keywords: chloride, chloride channels, constipation, functional bowel disorders, gastrointestinal motility, intestinal secretion, irritable bowel syndrome, lubiprostone

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4705-4706

Published Date: 5 December 2013

Making the certainty based marking pilot study a reality

Stone BA, Lemon TI

Advances in Medical Education and Practice 2013, 4:101-102

Published Date: 7 May 2013

Corrigendum

Jalil MA, Moongfangklang M, Innate K, Mitatha S, Ali J, Yupapin PP

International Journal of Nanomedicine 2012, 7:3279-3280

Published Date: 29 June 2012

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011

Corrigendum

Dove Medical Press Editorial

Clinical Interventions in Aging 2008, 3:397-397

Published Date: 30 June 2008